Clinical Trials

There are several clinical trials in process right now that support research for GBS, CIDP, and variants. Please note that this information is intended to help patients be aware of all of their options; the Foundation is unable to endorse any clinical trials.


International Guillain-Barré Syndrome Outcome Study (IGOS)

The international GBS Outcome Study (IGOS) is the largest and longest prospective trial designed to collect extensive data from patients afflicted with GBS in a systematic manner. The aim is to collect information from patients by intensive international collaboration. All patients are followed at standard intervals from the earliest phase of the disease up to at least one year after. At these time points all patients are clinically examined and documented according to the same protocol. The data generated from IGOS may fundamentally change how we care for patients with GBS and hasten research for more effective therapies.

The GBS|CIDP Foundation International is currently funding the IGOS trial through a research grant.


Baxalta/Quintile CIDP Treatment Trial

ADVANCE CIDP 1 Clinical Study

CIDP Treatment Trial, Now Enrolling Patients Worldwide!
Announcing a new study to investigate a potential new medication for CIDP patients. The ADVANCE-CIDPTM 1 Study is looking at a potential new treatment (an investigational medication) for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It will assess if the investigational medication could help to prevent muscle weakness in the upper and lower limbs. The investigational medication is an immunoglobulin (made from proteins found in the body called antibodies) and is given as an infusion under the skin every 2, 3, or 4 weeks.


About the study
The study is currently looking for 170 patients at approximately 90 study centers worldwide.
If you take part, you may be involved in the study for up to 14 months. The study is now
enrolling. Requirements include:
-Must be 18 years of age or older
-Must have been diagnosed with CIDP
-Must have been receiving treatment with immunoglobulin infusions at a stable dose, every 2–6 weeks, for at least 12 weeks (3 months)
Please visit clinicaltrials.gov and search for study identifier NCT02955355 for more information, including a list of participating countries and study centers:
CLICK HERE FOR MORE INFORMATION ON THE CURRENT TRIAL VIA CLINICALTRIALS.GOV

FIND OUT MORE HERE VIA SHIRETRIALS.COM


Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP

CSL Behring is conducting an open-label study to investigate the efficacy of single and multiple dose Privigen administration in IVIG‑pretreated and IVIG-untreated pediatric subjects with chronic inflammatory demyelinating polyneuropathy (CIDP).

ClinicalTrials.gov Identifier: NCT03684018

CLICK HERE FOR MORE INFORMATION ON THE CURRENT TRIAL VIA CLINICALTRIALS.GOV


A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

A Phase 1b Study to Evaluate the Safety, Tolerability and Drug-Drug Interactions of ANX005 and Intravenous Immunoglobulin (IVIg) in Subjects With Guillain Barré Syndrome

CLICK HERE FOR MORE INFORMATION ON THE CURRENT TRIAL VIA CLINICALTRIALS.GOV